Results 261 to 270 of about 7,543 (282)

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.

European journal of paediatric neurology
Doris Giess, Judit Erdos, Claudia Wild
semanticscholar   +1 more source

Nusinersen

Reactions weekly

semanticscholar   +1 more source

Cerebrospinal fluid proteomic profiling in nusinersen‐treated patients with spinal muscular atrophy

Journal of Neurochemistry, 2020
Markus Weiler, Tobias Kessler, Dominic Schmid   +2 more
exaly  

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries

Frontiers in Pharmacology, 2021
Teresa Barcina Lacosta, Mondher Toumi, Ran Tao   +2 more
exaly  

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA

Frontiers in Neurology, 2021
David Kline, Stephen J Kolb, W David Arnold   +2 more
exaly  

Computed‐tomography‐guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations

European Journal of Neurology, 2020
Stavros Spiliopoulos, Lina Palaiodimou, Dimitrios K Filippiadis   +2 more
exaly  

Hoher Zusatznutzen für Nusinersen

InFo Neurologie & Psychiatrie, 2018
openaire   +1 more source

Nusinersen in adults with spinal muscular atrophy: new challenges

The Lancet Neurology, 2020
Valeria A. Sansone, Eugenio Mercuri, Eugenio Mercuri   +2 more
openaire   +3 more sources

Nusinersen for older patients with spinal muscular atrophy: A real‐world clinical setting experience

Muscle and Nerve, 2020
Aravindhan Veerapandiyan
exaly  

Nusinersen auch nach Gentherapie nutzbringend

NeuroTransmitter, 2023
openaire   +1 more source